Profile data is unavailable for this security.
About the company
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
- Revenue in USD (TTM)443.00k
- Net income in USD-37.03m
- Incorporated2007
- Employees23.00
- LocationTrevena Inc955 Chesterbrook Boulevard, Suite 110CHESTERBROOK 19087United StatesUSA
- Phone+1 (610) 354-8840
- Fax+1 (302) 636-5454
- Websitehttps://www.trevena.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PaxMedica Inc | 0.00 | -17.66m | 1.52m | 6.00 | -- | -- | -- | -- | -7.54 | -7.54 | 0.00 | -0.2324 | 0.00 | -- | -- | 0.00 | -594.25 | -755.77 | -2,502.49 | -- | -- | -- | -- | -- | -- | -11,785.74 | -- | -- | -- | -- | -23.56 | -- | -- | -- |
| Panbela Therapeutics Inc | 0.00 | -28.56m | 1.55m | 7.00 | -- | -- | -- | -- | -84.64 | -84.64 | 0.00 | -2.18 | 0.00 | -- | -- | 0.00 | -197.23 | -215.89 | -3,522.07 | -476.38 | -- | -- | -- | -- | -- | -143.57 | -- | -- | -- | -- | 27.68 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -9.40m | 1.56m | 10.00 | -- | 0.0281 | -- | -- | -44.53 | -44.53 | 0.00 | 3.34 | 0.00 | -- | -- | 0.00 | -97.27 | -- | -121.76 | -- | -- | -- | -- | -- | -- | -19.61 | 0.0185 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
| Peak Bio Inc | 354.02k | -4.63m | 1.62m | -- | -- | -- | -- | 4.57 | -0.2066 | -0.2066 | 0.0135 | -0.9769 | 0.2192 | -- | -- | -- | -286.54 | -- | -- | -- | -- | -- | -1,307.11 | -- | -- | -4.85 | -- | -- | -39.46 | -- | 2.01 | -- | -- | -- |
| Trevena Inc | 443.00k | -37.03m | 1.65m | 23.00 | -- | -- | -- | 3.72 | -56.17 | -56.17 | 0.6391 | -22.23 | 0.0143 | -- | -- | 19,260.87 | -119.82 | -55.93 | -152.94 | -66.35 | -271.56 | -- | -8,358.24 | -3,134.41 | -- | -20.12 | 2.51 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
| GRI Bio Inc | 0.00 | -8.28m | 1.70m | 4.00 | -- | 0.0986 | -- | -- | -100.69 | -100.69 | 0.00 | 5.88 | 0.00 | -- | -- | 0.00 | -130.64 | -192.93 | -187.01 | -353.99 | -- | -- | -- | -37,650.49 | -- | -- | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
| Hi-Great Group Holding Co | 71.99k | -74.35k | 1.78m | -- | -- | -- | -- | 24.73 | -0.0007 | -0.0007 | 0.0007 | -0.0013 | 0.7149 | 0.627 | -- | -- | -73.83 | -- | -- | -- | 51.28 | -- | -103.28 | -- | 0.0099 | -20.74 | -- | -- | -47.32 | -- | -3,789.70 | -- | -- | -- |
| Aclarion Inc | 53.95k | -5.90m | 1.79m | 6.00 | -- | 0.89 | -- | 33.14 | -4.74 | -4.74 | 0.0146 | 0.20 | 0.0212 | -- | 3.59 | 8,991.67 | -231.70 | -- | -714.18 | -- | -51.53 | -- | -10,937.05 | -- | -- | -111.15 | 0.3212 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 1.83m | 15.00 | -- | 0.0925 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Kiromic Biopharma Inc | 0.00 | -26.21m | 1.86m | 35.00 | -- | -- | -- | -- | -19.73 | -19.73 | 0.00 | -3.35 | 0.00 | -- | -- | 0.00 | -167.49 | -161.04 | -- | -294.57 | -- | -- | -- | -- | -- | -7.22 | 1.74 | -- | -- | -- | 33.00 | -- | 8.52 | -- |
| Novelstem International Corp | 18.00k | -1.65m | 1.97m | 15.00 | -- | -- | -- | 109.39 | -0.0352 | -0.0352 | 0.0004 | -0.0541 | 0.0081 | -- | 8.00 | -- | -63.77 | -- | -- | -- | -- | -- | -7,867.33 | -- | -- | -2.13 | 2.61 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
| Ensysce Biosciences Inc | 1.44m | -11.28m | 2.01m | 7.00 | -- | 0.8017 | -- | 1.40 | -2.98 | -2.98 | 0.2845 | 0.2218 | 0.3142 | -- | 8.67 | 205,418.60 | -246.46 | -17.68 | -376.98 | -19.42 | -- | -- | -784.43 | -715.78 | -- | -5.93 | 0.235 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 10 Sep 2024 | 41.39k | 4.85% |
| Citadel Securities LLCas of 30 Jun 2024 | 6.05k | 0.71% |
| Geode Capital Management LLCas of 31 Aug 2024 | 4.51k | 0.53% |
| The Vanguard Group, Inc.as of 31 Aug 2024 | 2.89k | 0.34% |
| Virtu Americas LLCas of 30 Jun 2024 | 2.13k | 0.25% |
| Two Sigma Securities LLCas of 30 Jun 2024 | 1.38k | 0.16% |
| BBVA Asset Management SA SGIICas of 30 Jun 2024 | 921.00 | 0.11% |
| UBS Securities LLCas of 30 Jun 2024 | 878.00 | 0.10% |
| Fidelity Management & Research Co. LLCas of 31 Aug 2024 | 872.00 | 0.10% |
| Summit X LLCas of 30 Jun 2024 | 656.00 | 0.08% |
